Archive for the ‘Drugs’ Category

3rd Annual Best Practice in Phase IV Clinical & Observational Research

Monday, September 27th, 2010

Phase IV clinical trials are one the fastest growing areas of clinical research. Such post-marketing studies are becoming increasingly important as regulatory agencies demand more long-term data which proves efficacy, safety and quality. Furthermore, a key driver is the demands of health technology assessors and payers and their need for evidence-based economic data, again over the long-term. However, as post-marketing studies tend to be more commercial in nature, successfully planning and implementing them can be a major challenge, especially in terms of motivating investigators and recruiting patients who may already have access to the latest medications.

The event will provide the latest and most valuable, real-life experiences in post-marketing studies, their benefits and challenges. It will be an ideal opportunity for benchmarking and networking with the experts.

Why Attend?

  • Gain access to the latest methodologies and real-life cases in the field.
  • Explore how market leaders are improving data accuracy.
  • Balancing conflicting scientific, regulatory & marketing needs.
  • Learn more about comparative studies and their value for drug safety.
  • Understand how key figures are affecting future trends and standards.
  • Understand regulatory / ethical priorities.
  • Find out how phase IV studies & observational research are being outsourced and how industry players are selecting the right partners.

Who will benefit?

Pharmaceutical & Biotech companies Vice Presidents, Directors & Managers of: Medical Affairs, Epidemiology, Clinical Development & Operations, Drug Safety, Pharmacovigilance, Data Management, Regulatory Affairs, Clinical Outsourcing

Solution Providers: CROs, EDC & Data Management, Clinical Software, Market Access & Health Outcomes Consultancies
Academics & Doctors: Epidemiology, Principle Investigators, Primary Care
Government: Ministries of Health, Regulatory & Health Technology Assessment Agencies

Agenda request
To request the full agenda please follow the link:
http://www.nextlevelpharma.com/events/request_agenda/3rd_annual_best_practice_in_phase_iv_clinical_observational_research

For Booking Information contact:
Erika Vavrovicova

Tel: +421 232 660 382
Fax: +421 232 660 397
Email: erika@nextlevelpharma.com
Visit: www.nextlevelpharma.com

2nd Annual Pharmaceutical Risk-Sharing & Value-Based Pricing & Reimbursement Models

Monday, February 1st, 2010

Pharmaceutical Risk Sharing

There is clearly an increasing need for more innovative pricing and reimbursement agreements to help to balance the often conflicting objectives of pharmaceutical and medical technology manufacturers, payers, health technology assessors (HTA), physicians and patients. The industry faces a sustained increase in the cost of healthcare and an ever-increasing range of expensive drugs and technologies available as potential therapies.

Clearly, difficult choices need to be made by payers and HTAs about which products receive funding from increasingly restricted healthcare budgets, especially with often insufficient clinical and real-life evidence available. In terms of innovative agreements, more manufacturers, in more countries, are proposing risk-sharing and value-based schemes more often.

NextLevel Pharma has organized a unique meeting that will be focused purely on risk-sharing and value-based pricing schemes and will provide experts theories and practical case studies of successful models.

Why Attend?

  • Understand the opportunities, obstacles and challenges in designing and implementing innovative agreements.
  • Find out when risk-sharing & value-based agreements are required and how they can be designed to satisfy all stakeholders to gain market access.
  • Understand whether or not the turbulent macroeconomic environment will increase payer motivation for flexible agreements.
  • Obtain the best and most focused picture of risk-sharing and value-based pricing models today.
  • Learn how drug effectiveness is being demonstrated in different regions.
  • Understand the best ways to communicate value and achieve maximum patient and market access.
  • Hear the perspectives of all stakeholder groups: Payers, regulators, insurers, health economists and the pharmaceutical industry.
  • Discover how payers are evaluating conditional reimbursement agreements.

  • Who should attend?
    Pharmaceutical companies:

  • Vice-Presidents, Directors, Managers involved in:
  • Pricing & Reimbursement,
  • Market Access,
  • Health Economics & Outcomes,
  • Government & Stakeholder Relations,
  • Regulatory Affairs,
  • Medical Affairs,
  • Marketing & Commercial,
  • Therapy Area Heads,
  • Country Managers,
  • Business Unit Heads
  • Solution providers & consultants:
  • CEOs,
  • Business Development,
  • Senior Consultants,
  • Regional Heads.
  • Independent Academics, Health Economists, Senior Doctors, & Patient Representatives.

  • Agenda request
    To request the full agenda please follow the link:
    2nd Annual Pharmaceutical Risk-Sharing & Value-Based Pricing & Reimbursement Models

    For Booking Information contact:
    Erika Vavrovicova
    Tel: +421 232 660 382
    Fax: +421 232 660 397
    Email: erika@nextlevelpharma.com
    Visit: www.nextlevelpharma.com

    Training Course for Propofol Administration Now Available

    Sunday, December 6th, 2009

    Conscious Sedation Consulting announces the development of a course to educate non-anesthesia physicians and nurses in the administration of propofol. The company announced that a comprehensive didactic course will be provided internationally for physicians, staff and organizations which wish to add propofol administration to their choice of sedatives. The course covers patient selection, a comprehensive detailed explanation of the pharmacology and pharmacokinetics of propofol, BIS monitoring, computer-controlled infusions, airway management, physiological monitoring, as well as the prevention, recognition and management of adverse events. Also covered are documentation, accreditation standards, patient recovery, discharge, follow up and process improvement. The seminar uses as a foundation, an understanding of a culture of safety as described by the Institute of Medicine in its report To Err is Human.
    Propofol (2,6-diisopropyl phenol) is classified as an ultra-short-acting hypnotic agent that provides sedative, amnesic, and hypnotic effects. Propofol rapidly crosses the blood-brain barrier and causes a depression in consciousness that is likely related to potentiation of the g-aminobutyric acid A receptor in the brain.1 Propofol is 98% plasma-protein bound, and it is metabolized primarily in the liver by conjugation to its glucuronide and sulfate to produce water-soluble compounds that are excreted by the kidney. Typically, the time from injection to the onset of sedation is 30 to 60 seconds. Its duration of effect is 4 to 8 minutes. The pharmacokinetic properties do not significantly change in patients with renal failure or moderately severe chronic liver disease. Dose reduction is required in patients with cardiac dysfunction and in the elderly as a result of decreased clearance of the drug. Propofol potentiates the central nervous system effects of analgesics and sedatives such as benzodiazepines, barbiturates, narcotics, and other hypnotic/sedative agents. Therefore, the dose requirements of these agents may be reduced. The cardiovascular effects of propofol include decreases in cardiac output, systemic vascular resistance, and arterial pressure.2 Negative cardiac inotropy and respiratory depression can be seen with the use of propofol. These effects reverse rapidly with dose reduction or interruption of drug infusion3 and rarely require temporary ventilator support.

    Controversy surrounds the use of Propofol by non-anesthesia providers. This is in part due to the FDA approved package insert which states that propofol should be administered by individuals trained in the administration of general anesthesia. Additionally some independent practitioners are either unwilling or unable to administer propofol due to local institutional policies or in some cases state regulatory restrictions. In spite of such concerns propofol use has seen a dramatic increase over the last decade. A 2006 study published by the American Journal of Gastroenterolgy reported that 68% of US endoscopists using conventional sedation indicate that they would prefer to administer propofol but are reluctant to do so because of widespread perception of increased complication risks.4 Propofol is more widely used in other countries.

    John Hexem, MD, PhD, board certified anesthesiologist and co-founder of Conscious Sedation Consulting, LLC, stated “When used judiciously by physicians with specific training in the administration of propofol, it is a very nice drug. It has very favorable pharmacokinetic properties and patients regain full consciousness quickly, alert and comfortable. I have been administering propofol since 1991 and think it has definite advantages. Dr. Hexem also cautions that “proper monitoring and training that includes advanced airway management skills should be acquired prior to using this drug. Providers using propofol also need a thorough understanding of the continuum of sedation as described by the American Society of Anesthesiologists and national accrediting and safety organizations.

    Since 2002 more than 500,000 subjects have received propofol for endoscopic sedation.5
    From this data, propofol in appropriate patients with trained personnel has demonstrated an excellent safety record. Transient hypoxia occurs in 3% to 7% of cases and transient hypotension in 4% to 7%. Time to recovery ranged between 14 and 18 minutes. In a retrospective review of Nurse Administered Propofol Sedation (NAPS) in several centers and involving greater than 36,000 endoscopies, the rate of clinical adverse events, defined as apnea or airway compromise that required assisted ventilation via bag-mask, ranged from 0.1% to 0.2%. 6 No patients required intubation, and none had permanent injury or death.

    For additional information please visit online at www.SedationConsulting.com
    Or call at 1.888.581.4448.

    About: Conscious Sedation Consulting LLC, a patient safety advocacy firm that provides continuing education, training and consulting services to non anesthesia health care providers who offer sedation and analgesia services.

    Statement of Disclosure: It is the policy of Conscious Sedation Consulting LLC, its principles and any of its employees to disclose any financial interest or other relationship with a commercial interest producing healthcare goods or services that has a direct bearing on the subject matter of any educational activity. A relevant financial interest or other relationship may include such things as grants or research support or a relationship such as an employee, consultant, major stockholder, member of speaker’s bureau, and the like, that has been established for any dollar amount over the past 12 months. We have nothing to disclose.

    Conscious Sedation Consulting LLC
    27 Forest Lane
    Ofallon, MO 63366
    1.888.581.4448
    www.SedationConsulting.com

    1) Trapani G, Altomare C, Liso G, et al. Propofol in anesthesia: mechanism of action, structure-activity relationships, and drug delivery. Curr Med Chem 2007;7:249-71.

    2) White PF. Propofol pharmacokinetics and pharmacodynamics. Semin Anesth 1988;7:4-20.

    3) Short TG, Plummer JL, Chui PT. Hypnotic and anaesthetic interactions between midazolam, propofol and alfentanil. Br J Anaesth 1992;69: 162-7.

    4) Cohen LB, Wecsler JS, Gaetano JN, et al. Endoscopic sedation in the United States: results from a nationwide survey. Am J Gastroenterol 2006;101:967-74.

    5)Cohen LB, Hightower CD, Wood DA, et al. Moderate level sedation during endoscopy: a prospective study using low-dose propofol, meperidine/fentanyl, and midazolam. Gastrointest Endosc 2004;59: 795-803.

    6) Rex DK, Heuss LT, Walker JA, Qi R. Trained registered nurses/endoscopy teams can administer propofol safely for endoscopy. Gastroenterology 2005;129:1384-91.

    Webinar Series: Safety Biomarkers in Drug Development

    Friday, August 7th, 2009

     

     

    The ability to accurately predict adverse events related to areas like cardiology, nephrology, neurology, haematology and hepatology is extremely exciting. Validated safety biomarkers provide the opportunity for smarter and earlier decision making in R&D, meaning project „kill“ decisions are made quicker, later-stage projects become less risky and hundreds of millions of dollars can be saved.

    This webinar will summarise what are the most innovative recent scientific developments and the most promising regulatory initiatives, as well as providing a platform for partnering amongst the pharma, biotech, diagnostics and academic sectors.

    Why attend?

     

    • Understand the regulatory requirements to demonstrate safety through biomarkers.
    • Make partnerships and alliances with biomarker R&D experts.
    • Gain access to the latest successful biomarker development case studies.
    • Review multi-stakeholders perspectives: pharma, regulators, research institutes, academia & solution providers.
    • Learn how to integrate biomarker knowledge in monitoring safety in drug development to reduce risk.
    • Identify and understand better, advanced cardiac, renal, hepatological and neurological risk markers.
    • Discover cutting-edge approaches for identification and development of new markers.

    Who will benefit:

    Pharmaceutical, Biotech, Diagnostic & Academic research organisations:
    CEOs / Vice-Presidents / Heads / CSOs / Managers / Professors and Scientists involved in: R&D, drug safety & pharmacovigilance, biomarker discovery/validation, molecular diagnostics, pharmacogenomics/genetics/proteomics, translational medicine, clinical science and development, molecular imaging, pre-clinical development, modeling and simulation, pharmacology, pharmacokinetics/pharmacodynamics

    Solution providers & consultants:
    CEOs, Business Development, Senior Consultants, Regional Heads

     

    Agenda Request

    To request the full agenda please follow the link:

    https://www.nextlevelpharma.com/events/request_agenda/safety_biomarkers_in_drug_development

    Contact Details:

    For Booking Information:

    Tel: +421 232 662 621

    Fax: +421 232 660 395
    Email: erika@nextlevelpharma.com

    Visit: www.nextlevelpharma.com

    Next Generation Sequencing (NGS)Congress on November 2009

    Wednesday, August 5th, 2009

      • Next Generation Sequencing High Throughput Sequencing Platforms: Implementation and Technology Considerations
        Sequencing Applications Considerations
      • Applying Next-Generation Sequencing to Cancer and Medical Genetics and Discovery Research
      • Next Generation Sequencing Technologies and Bioinformatic Analysis Tools
      • Data Analysis
      • Data Management and Storage Strategies
    • Oxford Global Conferences is proud to present Next Generation Sequencing (NGS)Congress, which is to be held on the 16th & 17th November 2009 in London. The congress is held in conjunction with qPCR Congress( www.qpcr-congress.com).

       

      Next-generation sequencing technologies are revolutionizing biology by allowing for genome-wide transcription factor binding-site profiling, transcriptome sequencing, and more recently, whole-genome resequencing. These technologies will provide a genome-wide sequence readout as an endpoint to applications ranging from chromatin immunoprecipitation, mutation mapping and polymorphism discovery to noncoding RNA discovery.

       

      Over the 2 days, the conference provides an overview of the current options of next-generation sequencing platforms, technologies, applications and the newest computational tools for the analysis of next-generation sequencing data.

       

      The event will attract over 120 senior-level decision makers working in bioinformatics & data management, next generation sequencing, discovery, RNA profiling, molecular genomics, and clinical & diagnostics development from the UK, Europe and US.  This prestigious event provides a forum for practitioners and researchers to learn more about key solutions being provided to their industry, network with their peers, and address key industry concerns through a series of cutting edge conference presentations in a professional yet relaxed environment.

       

      THE EVENT

      In keeping with Oxford Global’s highly successful life sciences series, an expert panel of 25 speakers will present a full conference programme covering the following key topics include:

       

      Day 1 – 16th November

       

      Day 2 – 17th November

       

      WHO ATTENDS?

      Delegates are pre-qualified dependent on budget, responsibility and seniority.  Delegates are senior-level decision makers, from major pharmaceutical, biotech companies and research institutions based in Europe and typically include VPs, Directors, Managers and Heads of:

      Drug Discovery

      High throughput Technologies

      Bioinformatics

      Data Management

      Principal Investigation

      Molecular Profiling/Diagnostics

      Clinical Development

      qPCR

      Next Generation Sequencing

      Gene Expression

      Biostatistics

      Genomics

       

      YOUR NETWORKING OPPORTUNITIES

      Meet face-to-face with leading solution providers and senior-level industry peers through a series of formal and informal networking opportunities.  Using our online appointment system, you are able to view the full profiles of all solution provides before the event. In addition you have the chance to pre-arrange one-to-one meetings with them, giving you the opportunity to discuss technologies, services and solutions that address your key business needs.   Categories of solution providers include:

       

      Next Generation Sequencing Platforms

      NGS technologies

      Screening Technologies

      High Throughput Sequencing

      Data Management Methods

      Bioinformatics/Biostatistics Solutions

       

       

      Special discounts are available by quoting NGSDEL09. For information on sponsorship and registration please email info@oxfordglobal.co.uk or call +44(0) 1865 304925 www.nextgenerationsequencing-congress.com.

       

       

    qPCR Congress 2009 in UK this November

    Sunday, August 2nd, 2009

      • Successful Gene Expression Analysis using real-time PCR
      • Profiling technologies: multivariate and multiway expression profiling, temporal expression profiling and spatiotemporal maps
      • Other technologies: High resolution melt, Immuno PCR, Methylation sensitive PCR, SNP analysis, microRNA detection and Multiplex technologies
      • Development of clinical diagnostics and clinical Development – use in therapeutic areas such as cancer and infectious diseases
      • Bioinformatics
      • Data management: software applications, data mining, data visualization, biostatistics, multivariate statistics
      • Assay optimisation and validation strategies
      • New applications of qPCR- High throughput applications, Real-time RT-PCR arrays and Digital PCR
      • The discovery of Biomarkers: Disease markers, Tissue specific markers, Cancer markers, Stem cells, Differentiation markers and Cancer stem cells
      • The potential and use of qPCR reagents and instrumentation
    • Oxford Global Conferences is proud to present qPCR Congress 2009 (www.qpcr-congress.com), which is to be held on the 16th & 17th November 2009 in London. The congress is the single most focused event in Europe dedicated to key technological and scientific trends & advances in qPCR in the pharmaceutical and biotech industry, as well as academic institutions. There is also a post conference workshop on Biostatistics on the 18th November.

       

      This conference explores effective strategies, technologies and applications of qPCR in accelerating drug discovery and the development of clinical diagnostics. Over three days, the event will attract over 120 senior-level decision makers working in discovery, biomarkers, gene expression, molecular biology, and clinical & diagnostics development and bioinformatics & data management from the UK, Europe and US.  This prestigious event provides a forum for practitioners and researchers to learn more about key solutions being provided to their industry, network with their peers, and address key industry concerns through a series of cutting edge conference presentations in a professional yet relaxed environment.

       

      THE EVENT

      In keeping with Oxford Global’s highly successful life sciences series, an expert panel of 45 speakers will present a full conference programme covering the following key topics include:

       

      Day 16th November

      Stream 1: qPCR in Diagnostics and Molecular Markers as well as Novel Technical Approaches

      Stream 2: Bioinformatics and Data Management

      Day 2 17th November

      Stream 1: qPCR in Drug Discovery and Development

      Stream 2: Next Generation Sequencing High Throughput Sequencing Platforms

       

      Day 3 18th November: Post Conference Workshop – Biostatistics

       

      WHO ATTENDS?

      Delegates are pre-qualified dependent on budget, responsibility and seniority.  Delegates are senior-level decision makers, from major pharmaceutical, biotech companies and research institutions based in Europe and typically include VPs, Directors, Managers and Heads of:

       

      Drug Discovery

      Biomarkers

      Bioinformatics

      Clinical Diagnostics

      Principal Investigators

      Molecular Profiling

      Clinical Development

      qPCR

      Gene Expression

       

       

       

      Toxicology

      Translational Science

      Biochemistry

      Genomics

      Biostatistics

      High throughput Technologies

      Data Management

      Cell Biology

       

      YOUR NETWORKING OPPORTUNITIES

      Meet face-to-face with leading solution providers and senior-level industry peers through a series of formal and informal networking opportunities.  Using our online appointment system, you are able to view the full profiles of all solution provides before the event.  In addition you have the chance to pre-arrange one-to-one meetings with them, giving you the opportunity to discuss technologies, services and solutions that address your key business needs.  Categories of solution providers include:

       

      Real-Time PCR Reagents & Instrumentation

      qPCR technologies

      Screening Technologies

      Gene Expression Services

      RNAi Applications

      Bioinformatics/Biostatistics Solutions

      Molecular & Expression Profiling

      High Throughput Sequencing

      Data Management Methods

      Multiplex Technologies

      Sampling Technologies

      Multimarker Diagnostics

       

       

      Special discounts are available by quoting qPCRDEL09. For information on sponsorship and registration please email info@oxfordglobal.co.uk or call +44(0) 1865 304925 www.qpcr-congress.com.

       

       

    Improving Drug Design for Children

    Thursday, July 16th, 2009

    pediatric_banner.jpg

    This will be a half day webinar for clinical pharmacologists, scientists and pediatricians to discuss overcoming the scientific challenges in designing PK/PD studies to aid developing new pediatric medicines.

    NextLevel Pharma’s focused and interactive webinar will look to concentrate on the position that pharmacokinetic and pharmacodynamic modelling and simulations have to answer the questions of how children metabolize drugs differently, how to assess optimal drug dosage levels and optimise the design of pediatric studies.

    Experienced industry pharmacologists and pediatricians will join us to discuss recent developments and assess how to better understand drug interaction, determine the optimal dosage and report on efficacy in children.

    Why participate?

    • Understand the need for pk/pk studies: the when, how and why in the eyes of the regulators.
    • Learn what roles pk/pd studies have in the development of pediatric drugs and how they can be used more effectively to determine dosages, measure efficacy and demonstrate value to the pediatric world.
    • Hear case study presentations from industry leaders on how to adapt methods used from adult to children and gain fresh perspectives from experienced pharmaceutical companies who have successfully integrated pk/pd into pediatric studies for optimal design.
    • Discover which approaches are best to predict dosage, utilize existing (adult) data, and understand the interactions between drug and child.

    Who will benefit:

    Pharmaceutical & Biotechnology Organisations:
    Vice- Presidents, Directors, Managers;
    Pediatrics, Pre-Clinical and Clinical Pharmacologists, Modelling and simulation specialists.

    Academics;
    Pediatricians, pharmacologists and scientists involved in the development of new pediatric medicines

    Agenda Request

    To request the full agenda please follow the link:

    https://www.nextlevelpharma.com/events/request_agenda/pediatric_pharmacology

    Contact Details:

    For Booking Information:

    Tel: +421 232 662 621

    Fax: +421 232 662 622

    Email: erika@nextlevelpharma.com

    Visit: www.nextlevelpharma.com

     

    Safety Biomarkers in Drug Development

    Tuesday, June 16th, 2009

    The ability to accurately predict adverse events related to areas like cardiology, nephrology, neurology, haematology and hepatology is extremely exciting. Validated safety biomarkers provide the opportunity for smarter and earlier decision making in R&D, meaning project „kill“ decisions are made quicker, later-stage projects become less risky and hundreds of millions of dollars can be saved.

    This conference will summarise what are the most innovative recent scientific developments and the most promising regulatory initiatives, as well as providing a platform for partnering amongst the pharma, biotech, diagnostics and academic sectors.

    Why attend?

    • Understand the regulatory requirements to demonstrate safety through biomarkers.
    • Make partnerships and alliances with biomarker R&D experts.
    • Gain access to the latest successful biomarker development case studies.
    • Review multi-stakeholders perspectives: pharma, regulators, research institutes, academia & solution providers.
    • Learn how to integrate biomarker knowledge in monitoring safety in drug development to reduce risk.
    • Identify and understand better, advanced cardiac, renal, hepatological and neurological risk markers.
    • Discover cutting-edge approaches for identification and development of new markers.

    Who will benefit:

    Pharmaceutical, Biotech, Diagnostic & Academic research organisations:
    CEOs / Vice-Presidents / Heads / CSOs / Managers / Professors and Scientists involved in: R&D, drug safety & pharmacovigilance, biomarker discovery/validation, molecular diagnostics, pharmacogenomics/genetics/proteomics, translational medicine, clinical science and development, molecular imaging, pre-clinical development, modeling and simulation, pharmacology, pharmacokinetics/pharmacodynamics

    Solution providers & consultants:
    CEOs, Business Development, Senior Consultants, Regional Heads

    Agenda Request

    To request the full agenda please follow the link:

    https://www.nextlevelpharma.com/events/request_agenda/safety_biomarkers_in_drug_development

    Contact Details:

    For Booking Information:

    Tel: +421 232 662 621

    Fax: +421 232 660 395
    Email:
    erika@nextlevelpharma.com

    Visit: www.nextlevelpharma.com

    2nd ANNUAL PHARMACEUTICAL PRICING & REIMBURSEMENT IN CENTRAL & EASTERN EUROPE

    Friday, March 27th, 2009

    How important is it for you to gain first- hand access to information on upcoming healthcare budget reforms?

    How informed are you on market conditions and opportunities for CEE drug markets in current challenging economic conditions?

    NextLevel Pharma is organising the timely meeting which will present a fresh and original perspective on communicating the cost-effectiveness of high valued drugs to key stakeholders in the former communist countries of Central and Eastern Europe (CEE EU members, The Balkans and the former Soviet states). 

    Implementing innovative market access aproaches in an exciting & complex market

    4th-5th June, 2009; Prague, Czech Republic

    Pre-conference day, 3rd June 2009- Pharmaceutical Market Access in BRIC countries

    Exploring analysis & reimbursement models in large growth markets: Brazil, Russia, India & China

    By attending this event you will:

    • Understand the realistic market conditions and opportunities for CEE drug markets in current chalenging economic conditions.
    • Hear experiences from ministries of health and industry leaders; overcome the challenges they are facing in times of transition and hear their most up to date solutions and future trends.  
    • Learn how HTAs are established and structured in CEE and understand the best ways to achieve maximum market access in the region.
    • Benchmark, network and co-operate with policy makers and key opinion leaders. Get the best and most focused picture of today’s workable reimbursement models and gain first hand access to information on upcoming healthcare budget reforms.

    Who will benefit:

    Pharmaceutical manufacturers:
    Vice-Presidents, Directors, Managers involved in:
    Pricing & Reimbursement, Health Outcomes, Government Affairs, Regulatory Affairs, Medical, Marketing, CEE Heads, Country Heads, Pre-Marketing / Clinical Data Collection

    Solution providers & consultants:
    CEOs, Business Development, Senior Consultants, Regional Heads

    Speakers include:
    Policy Makers

    • Ministry of Health, Republic of Serbia – Deputy Minister
    • World Health Organization, Switzerland- Coordinator, Health Technology and Facilities
    • University Hospital Zagreb- Member of Croatian Parliament Health and Social Welfare Committee
    • National Medicines Agency, Romania- Head of European Integration Service
    • Reforma Zdravotnictvi, Czech Republic- Adviser to Czech Minister of Health

    Market Access Advocates

    • University Of Lyon, France- Prof. of Market Access
    • CEE Society of Technology Assessment in Healthcare- Senior Consultant
    • The Corvinus University of Budapest-  Associate Professor
    • Slovenian Lymphoma Patients Association- Chairman

    Industry Experts

    • Novartis Pharma GmbH, Germany- Head of Health Care Management
    • Wyeth, Switzerland- Senior Director of P&R EMEAC
    • Solvay Pharmaceuticals, Germany- Area Director EE
    • Genzyme, Czech Republic- General Manager South Central Europe 
    • IPSEN, Ukraine & Moldova- General Manager
    • GlaxoSmithKline Romania- Government Affairs Director
    • AstraZeneca, Hungary- Medical Director
    • Bayer AG, Hungary- Governmental Affairs Manager

    Together, they will deliver knowledge, expertise, insights, opinions, facts and data that can add strategic intelligence and real-value to your business.

    Agenda Request:
    To request the agenda, registration form and to learn more about this event, please follow the link:

    http://www.nextlevelpharma.com/events/request_agenda/24
    In case you have any problems with link, please contact me directly and I will send the agenda to you immediately.

      •                                                     

    Contact:

    Erika Vavrovicova

    NextLevel Pharma

    ph: +421 2 3266 2621

    fax: +421 2 3266 0395

    erika@nextlevelpharma.com

    Risk-Sharing & Value-Based Pricing and Reimbursement Schemes

    Wednesday, March 25th, 2009

    How interested are you to gain preferential market access via innovative payer agreements?

    NextLevel Pharma is organising the only meeting looking at risk-sharing and value-based pricing and reimbursement schemes.

     

    Achieving preferential market-access through innovative agreements with payers

    ( Brussels, Belgium, 23rd- 24th April, 2009)

    This will be an ideal opportunity to understand and learn from the experiences and opinions of other pharma and medical devices companies, HTA agencies, payers and keystakeholders and benchmark globally.

    Find your reasons to Attend:

    • Understand what are the most up to date, innovative agreement solutions and future trends in different countries globally
    • Learn how drug effectiveness, value and safety are being demonstrated in deferent regions.
    • Benchmark, network and co-operate with policy makers and key, influential figures. Get the best and most focused picture of risk-sharing and value-based pricing models today.
    • Hear the perspectives of all stakeholder groups: Ministries of Health, HTA Agencies, Insurers, Doctors, Patients and Patient Groups, Health Economists and the Pharmaceutical Industry.
    • Discover how payers are evaluating a range of complex pricing and reimbursement agreements.
    • Understand what patients want and what they define as a quality treatment, that enhances their lives.
    • Find out if risk-sharing and value-based pricing schemes can help pharma and medical device manufactures achieve preferential
    • market access and a competitive advantage.
    • Understand the best ways to comunicate value with stakeholders and achieve maximum patient and market access.

    Speakers include:

       GlaxoSmithKline, UK- Director Global Health Outcomes, Oncology
       Novartis, Switzerland- Global Brand Pricing & Reimbursement Director
      Astellas, UK- Vice President, Medical Affairs & Health Economics Europe
       Medtronic- Director, Reimbursement and Health Economics, Central and Eastern Europe, Greece and Israel
       Indiana Office of Medicaid Planning and Policy, USA- Director, Health Quality, Policy Research and Strategic Planning
      OHE, UK- Director of the Office of Health Economics
      NHS Innovations London- Head of Health Outcomes Unit
      Tufts Center for the Study of Drug Development, USA- Associate Director
      Luiss University & Business School, Rome- Healthcare and Pharmaceutical Economics and Polices
       Oncology Center Antwerp- Director
       Tufts Center for the Study of Drug Development, USA- Associate Director
       Luiss University & Business School, Rome- Healthcare and Pharmaceutical Economics and Polices
       Oncology Center Antwerp- Director

    Together, they will deliver knowledge, expertise, insights, opinions, facts and data that can add strategic intelligence and real-value to your business.

    Agenda Request:
    To request the agenda, registration form and to learn more about this event, please follow the link:

    http://www.nextlevelpharma.com/events/request_agenda/22
    In case you have any problems with link, please contact me directly and I will send the agenda to you immediately.

      •   

    CO-LOCATED EVENT

    MARKET ACCESS STRATEGIES FOR PERSONALISED MEDICINES

    AND COMPANION DIAGNOSTICS

    BUILDING  VALUE-PROPOSITION AND BUSINESS MODEL TO REALISE THE FULL COMMERCIAL POTENTIAL OF PERSONALISED HEALTHCARE

    (Brussels, April 21-22nd April)

      Contact:

    Erika Vavrovicova

    NextLevel Pharma

    ph: +421 2 3266 2621

    fax: +421 2 3266 0395

    erika@nextlevelpharma.com